Pfizer Acquires Global Blood Therapeutics for $5.4 Billion

Boston Scientific Acquires BTG plc

August 19, 2019

Medical Devices

Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.

GlaxoSmithKline Acquires Sierra Oncology for $1.9bn

April 13, 2022

Biotechnology

GlaxoSmithKline plc (GSK) has agreed to acquire late-stage biopharmaceutical company Sierra Oncology for $55 per share in cash, representing an approximate equity value of $1.9 billion. The acquisition, expected to close in Q3 2022 subject to customary approvals, brings momelotinib — a late-stage JAK/ACVR1 inhibitor with demonstrated benefit on symptoms, splenic response and anaemia in myelofibrosis — into GSK's haematology portfolio to strengthen its specialty medicines capability and global commercial reach.

Amgen Acquires Dark Blue Therapeutics

January 6, 2026

Biotechnology

Amgen has acquired Dark Blue Therapeutics, an Oxford-based biotechnology company focused on targeted protein degraders for oncology, in a deal valued at up to $840 million including upfront and milestone payments. The acquisition adds Dark Blue's preclinical MLLT1/3 degrader program (DBT-3757) to Amgen's early oncology discovery efforts and will be integrated into Amgen's existing R&D organization.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Biotechnology

Gilead Sciences has completed the acquisition of CymaBay Therapeutics for approximately $4.3 billion, paying $32.50 per share in cash. The deal adds CymaBay's investigational PPARδ agonist seladelpar for primary biliary cholangitis (PBC) to Gilead's liver-disease portfolio and is expected to accelerate development and potential commercialization of the therapy.

Bristol Myers Squibb Acquires Turning Point Therapeutics

June 3, 2022

Biotechnology

Bristol Myers Squibb agreed to acquire clinical-stage precision oncology company Turning Point Therapeutics in an all-cash transaction valuing the company at approximately $4.1 billion ($76.00 per share). The deal adds Turning Point's lead asset, repotrectinib, and its precision oncology pipeline to BMS's oncology franchise and is expected to close in 2022 (tender offer completed and merger subsequently closed).

Takeda Acquires GammaDelta Therapeutics

October 27, 2021

Biotechnology

Takeda Pharmaceutical Company Limited has exercised its option to acquire GammaDelta Therapeutics Limited, obtaining the company's allogeneic Vδ1 γδ T cell therapy platforms and early-stage cell therapy programs. The acquisition, stemming from a multi-year collaboration begun in 2017, is for a pre-negotiated upfront payment plus potential milestone payments and is expected to close in Q1 of Takeda's fiscal 2022, subject to antitrust review.